VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) EBIT : $-7.05 Mil (TTM As of Jun. 2008)

View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals EBIT?

VioQuest Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2008 was $-1.03 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2008 was $-7.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. VioQuest Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2008 was -8,939.13%. VioQuest Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2008 was -13,264.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

VioQuest Pharmaceuticals EBIT Historical Data

The historical data trend for VioQuest Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals EBIT Chart

VioQuest Pharmaceuticals Annual Data

Trend

Dec98

Dec99

Dec00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

EBIT

Get a 7-Day Free Trial

-2.03

-4.06

-10.40

-5.28

-8.78

VioQuest Pharmaceuticals Quarterly Data
	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08
EBIT	Get a 7-Day Free Trial															-2.14	-2.67	-1.68	-1.67	-1.03

Competitive Comparison of VioQuest Pharmaceuticals's EBIT

For the Biotechnology subindustry, VioQuest Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VioQuest Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VioQuest Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where VioQuest Pharmaceuticals's EV-to-EBIT falls into.

VioQuest Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.05 Mil.

VioQuest Pharmaceuticals (OTCPK:VOQP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

VioQuest Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2008 is calculated as:

	ROC % (Q: Jun. 2008 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2008 )	+	Invested Capital (Q: Jun. 2008 ))	/ count )
=	-4.112 * ( 1 - 0% )	/	( (0.047	+	0.045)	/ 2 )
=	-4.112	/	0.046
=	-8,939.13 %

where

	Invested Capital		(Q: Mar. 2008 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.698	-	3.452	-	( 0.306	-	max(0, 3.452	-	0.651	+	0.306	))
=	0.047

	Invested Capital		(Q: Jun. 2008 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.177	-	2.694	-	( 0.814	-	max(0, 2.694	-	1.132	+	0.814	))
=	0.045

Note: The Operating Income data used here is four times the quarterly (Jun. 2008) data.

2. Joel Greenblatt's definition of Return on Capital:

VioQuest Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2008 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2008 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2008		Q: Jun. 2008
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.112	/	( ( (0.032 + max(-3.107, 0))	+	(0.03 + max(-2.376, 0)) )	/	2 )
=	-4.112	/	( ( 0.032	+	0.03 )	/	2 )
=	-4.112	/	0.031
=	-13,264.52 %

where Working Capital is:

	Working Capital		(Q: Mar. 2008 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.345)	-	(3.452	+	0	+	0)
=	-3.107

	Working Capital		(Q: Jun. 2008 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.318)	-	(2.694	+	0	+	0)
=	-2.376

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2008) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

VioQuest Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2008 )
	=	-7.05	/	0.000
	=	%

VioQuest Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 2287, Minneapolis, MN, USA, 55402

Website

VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.

Executives

Mark D Dacko	director, officer: CFO and Secretary	800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker	officer: V.P. & Chief Financial Officer	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz	officer: CFO and Treasurer	65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam	director
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli	director, officer: Secretary	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf	director, officer: President and CEO	C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz	10 percent owner	WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen	director	TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines